Skip to main content
Terug
Watch Compare

Benitec Biopharma Inc.

Datakwaliteit: 83%
BNTC
Nasdaq Manufacturing Chemicals
€ 11,42
▲ € 0,41 (3,72%)
Marktkapitalisatie: 377,15 M
Prijs
€ 11,01
Marktkapitalisatie
377,15 M
Dagbereik
—
52-Weeksbereik
—
Volume
—
Openen —
50D / 200D Gem.
—
50D / 200D Gem.
—

Quick Summary

Belangrijkste Punten

Negative free cash flow of -26,16 M

Groei

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
-38,20%
Boven sectorgemiddelde (-53,41%)
ROIC-33,16%
Net MarginN/A
Op. MarginN/A

Veiligheid

Debt / Equity
N/A
Current Ratio67,69
Interest CoverageN/A

Waardering

PE (TTM)
-7,03
Onder sectorgemiddelde (-1,48)
P/B Ratio2,01
EV/EBITDAN/A
Dividend YieldN/A

Koershistorie

Financiële Trends

Sectorvergelijking

vs Manufacturing sector mediaan (1364 peers)
Metriek Aandeel Sector Mediaan
P/E -7,0 -1,5
P/B 2,0 1,6
ROE % -38,2 -53,4
Net Margin % — -41,5
Rev Growth 5Y % — 1,8
D/E — 0,3

ETFs Holding This Stock

PINK logo PINK Simplify Health Care ETF
0,62% weight
IRSSX IRSSX
0,01% weight
VVICX VVICX
0,01% weight
IRSIX IRSIX
0,01% weight
IIRSX IIRSX
0,01% weight
IRCIX IRCIX
0,01% weight

All Fundamental Metrics
Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) N/A Net Income (TTM) -53,66 M
ROE -38,20% ROA -37,43%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -26,16 M
ROIC -33,16% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 67,69
Interest Coverage N/A Asset Turnover N/A
Working Capital 186,79 M Tangible Book Value 187,36 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -7,03 Forward P/E N/A
P/B Ratio 2,01 P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -6,94%
Market Cap 377,15 M Enterprise Value 188,36 M
Per Share
EPS (Diluted TTM) -1,05 Revenue / Share N/A
FCF / Share -0,76 OCF / Share -0,76
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 48,75%
SBC-Adj. FCF -42,69 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue — — — — 59.000,0
Net Income -37,92 M -21,75 M -19,56 M -18,21 M -13,88 M
EPS (Diluted) -1,05 -5,51 -14,12 -2,23 —
Gross Profit — — — — —
Operating Income -41,77 M -22,49 M -19,08 M -17,85 M -13,60 M
EBITDA — — — — —
R&D Expenses 18,33 M 15,61 M 12,77 M 11,27 M 7,02 M
SG&A Expenses — — — — —
D&A 66.000,0 87.000,0 136.000,0 167.000,0 231.000,0
Interest Expense — — — — —
Income Tax — — — — —

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 99,59 M 52,21 M 4,46 M 5,97 M 21,38 M
Total Liabilities 2,30 M 4,96 M 4,26 M 3,09 M 1,37 M
Shareholders' Equity 97,30 M 47,25 M 202.000,0 2,88 M 20,01 M
Total Debt — — — — —
Cash & Equivalents 97,74 M 50,87 M 2,48 M 4,06 M 19,77 M
Current Assets 98,52 M 51,67 M 3,73 M 4,82 M 20,61 M
Current Liabilities 1,80 M 4,92 M 3,98 M 2,53 M 1,37 M